Nuclease resistant methylphosphonate-DNA/LNA chimeric oligonucleotides by Nagahama, Koji et al.
Bioorganic & Medicinal Chemistry Letters 19 (2009) 2707–2709Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclNuclease resistant methylphosphonate-DNA/LNA chimeric oligonucleotides
Koji Nagahama, Rakesh N. Veedu, Jesper Wengel *
Nucleic Acid Center, Department of Physics and Chemistry, University of Southern Denmark, Campusvej 55, Odense M 5230, Denmark
a r t i c l e i n f o a b s t r a c tArticle history:
Received 9 March 2009
Revised 23 March 2009
Accepted 25 March 2009
Available online 28 March 2009
Keywords:
LNA
Antisense
RNA targeting
Methylphosphonate-DNA
Nuclease stability0960-894X/$ - see front matter  2009 Elsevier Ltd. A
doi:10.1016/j.bmcl.2009.03.116
* Corresponding author. Tel.: +45 6550 2510; fax: +
E-mail address: jwe@ifk.sdu.dk (J. Wengel).Synthesis of chimeric 9-mer oligonucleotides containing methylphosphonate-linkages and locked nucleic
acid (LNA) monomers, their binding affinity towards complementary DNA and RNA, and their 30-exonu-
cleolytic stability are described. The obtained methylphosphonate-DNA/LNA chimeric oligonucleotides
display similarly high RNA affinity and RNA selectivity as a corresponding 9-mer DNA/LNA chimeric oli-
gonucleotide, but much higher resistance towards 30-exonucleolytic degradation.
 2009 Elsevier Ltd. All rights reserved.Antisense oligonucleotides (AONs) targeting RNA have been
widely used to evaluate gene function in vitro and in vivo,1–4 and
several antisense therapeutics are in clinical trials.5,6 In order to
be effective and practically useful in the above technologies, AONs
should feature specific characteristics including high-target RNA
binding affinity, sequence specificity and nuclease resistance.
Phosphorothioate DNA oligonucleotides, which have been the most
widely used AONs, exhibit nuclease resistance, but have a number
of limitations, such as sequence independent toxicity, immune
stimulation and low RNA affinity.7–9 Numerous modified oligonu-
cleotides (ONs) have been developed in the past few decades to im-
prove the properties of AONs.10–15 Locked nucleic acid (LNA, Fig. 1),
which is a conformationally restricted RNA mimic displaying
unprecedented binding affinities towards complementary single
stranded RNA or DNA,16–19 is a promising modification for AON
applications,20–22 and is currently being utilized in various genomic
technologies.23–26 Introduction of consecutive LNAmonomers from
the 30-end of an AON efficiently protects against 30-exonucleolytic
degradation,16 whereas isolated LNA monomers in DNA/LNA chi-
meric AONs offer no significant protection.21 To ensure sufficient
biostability of DNA/LNA chimeric AONs, the use of phosphorothio-
ate linkages throughout the AON has proven very efficient.27,28
Methylphosphonate-DNA (MP-DNA, Fig. 1) is another class of
potential AONs which contain non-ionic internucleoside link-
ages.29–31 MP-DNA displays stabilization towards nucleolytic deg-
radation but unfortunately also significantly reduced binding
affinity towards complementary RNA.32–34 In a first attempt ofll rights reserved.
45 6550 4385.combining the desirable properties of methylphosphate linkages
and LNA monomers, we reported synthesis, satisfactory RNA bind-
ing properties and increased 30-exonucleolytic stability of ONs con-
taining a single methylphosphonate-LNA (MP-LNA, Fig. 1)
monomer.35 However, the fact that MP-LNA monomers are not
commercially available has hampered further exploration of this
class of potential AONs. Herein, we describe solid phase synthesis
of chimeric 9-mer ONs containing MP-DNA and LNA monomers
(MP-DNA/LNA) together with their DNA/RNA binding properties
and stability against 30-exonucleolytic degradation. Our aim is to
develop AONs devoid of phosphorothioate linkages which combine
stability under physiological conditions and high RNA binding
affinity with easy availability.
MP-DNA/LNA ONs (ON4 and ON6, Table 1) and MP-DNA/DNA
ONs (ON3 and ON5, Table 1) containing different number of MP-
linkages (monomers GMe or AMe) were synthesized in 1.0 lmol
scale by automated solid phase DNA synthesis using commercially
available MP-DNA and LNA-T phosphoramidites. The step-wise
coupling efficiencies, based on the absorbance of the dimethoxytri-
tyl cation released after each coupling step, of all monomers were
>98% when applying standard conditions as recommended by sup-
pliers. The chimeric ONs were, as O50-DMT-ON derivatives, depro-
tected and simultaneously cleaved off the solid support using a
mixture of ethylenediamine and ethanol (1/1, v/v) at 55 C for
55 min.36 Subsequent purification by RP-HPLC followed by detrity-
lation provided the fully deprotected ONs. After purification, the
purities (>80%) and composition of ON3–ON6 were characterized
by RP-HPLC and MALDI-TOF mass spectrometry, respectively.37
The ability of the MP-DNA/LNA ONs to form duplexes with com-
plementary RNA and DNA in medium salt buffer (120 mM [Na+])
Table 1
Tm values (C) of the oligonucleotides used in this study towards complementary single-stranded DNA and RNAa
Sequence Tm with DNA (C) Tm with RNA (C)
120 mM [Na+]b (DTm) 30 mM [Na+]c (DTm) 120 mM [Na+]b (DTm) 30 mM [Na+]c (DTm)
50-d(GTGATATGC) (ON1) 29 (±0) 14 (±0) 27 (±0) 16 (±0)
50-d(GTLGATLATLGC) (ON2) 44 (+15) 28 (+14) 53 (+26) 36 (+20)
50-d(GTGMeATAMeTGC) (ON3) 27 (–2.0) 15 (+1.0) 22 (–5) <10d (n.d.e)
50-d(GTLGMeATLAMeTLGC) (ON4) 39 (+10) 27 (+13) 47 (+20) 39 (+23)
50-d(GMeTGMeAMeTAMeTGMeC) (ON5) 25 (–4.0) 18 (+4.0) <10d (n.d.e) <10d (n.d.e)
50-d(GMeTLGMeAMeTLAMeTLGMeC) (ON6) 34 (+5.0) 28 (+14) 40 (+13) 33 (+17)
a Tm values were obtained as the maximum of the first derivative of the melting curve (A260 vs temperature) in buffer using 1.0 lM concentrations of the two components.
DTm values calculated relative to the all-DNA reference ON1 are shown in parentheses. TL = thymin-1-yl LNA monomer, AMe = adenine-9-yl DNA methylphosphonate
monomer, GMe = guanin-9-yl DNA methylphosphonate monomer.
b Tm values measured in medium salt buffer (100 mM NaCl, 10 mM NaH2PO4, 5 mM Na2HPO4, 0.1 mM EDTA, pH 7.0).
c Tm values measured in low salt buffer (10 mM NaCl, 10 mM NaH2PO4, 5 mM Na2HPO4, 0.1 mM EDTA, pH 7.0).
d No cooperative transition above 10 C was observed.
e Not determined.
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Figure 1. Structures of the thymine nucleotide monomers of DNA, methylphosphonate DNA, LNA and methylphosphonate LNA.
2708 K. Nagahama et al. / Bioorg. Med. Chem. Lett. 19 (2009) 2707–2709was evaluated by UV melting experiments (Table 1). Reference du-
plex melting temperatures (Tm values) were obtained for the corre-
sponding all-DNA (ON1), DNA/LNA (ON2) and MP-DNA/DNA (ON3
and ON5) ONs. As reported earlier33,34 introduction of MP-DNA
monomers into DNA (ON3 and ON5) induced decreased Tm values.
We furthermore note an additive affinity-decreasing effect of MP-
DNA monomers, especially towards complementary RNA. As re-
ported earlier, introduction of three LNA monomers into a DNA
ON results in significantly increased Tm values (ON2 relative to
ON1). The data obtained for the MP-DNA/LNA chimeras ON4 and
ON6 reflect high-affinity targeting of DNA/RNA complements also
for these constructs, and the affinity-decreasing effect on the MP-
DNA monomers is more than counterbalanced by the affinity-
enhancing effect of LNA monomers. Furthermore encouraging in
light of AON development is the fact that the MP-DNA/LNA chime-
ras display RNA targeting selectivity in line with the parent DNA/
LNA chimeras.Figure 2. Snake venom phosphordiesterase degradation of [32P]-labelled DNA (ON1), DN
numbers above the lanes indicate the time of incubation (in minutes).Next, the effects of sodium ion concentration on the Tm values
of the chimeric ONs were investigated (Table 1). As expected,
decreasing salt concentration (from 120 to 30 mM NaCl) destabi-
lized the duplexes, even for ON3–ON6 containing non-ionic meth-
ylphosphonate linkages. Although the affinity-decreasing effect
was also observed for the MP-DNA/LNA chimeric ONs, ON4 con-
taining two MP-linkages and three LNA monomers showed
remarkably higher Tm value (DTm > 30 C) towards RNA relative
to ON3 containing two MP-linkages without LNA modification. A
similar trend was observed for ON6 relative to ON5.
Stability towards nucleolytic degradation is an important factor
when applying AONs in biological systems, and it has been re-
ported that 30-exonucleolytic activity is the primary cause of
AON degradation. The susceptibility of ON1–ON6 towards the 30-
exonuclease snake venom phosphodiesterase (SVPDE)38 was eval-
uated (Fig. 2). The ONs were 50-32P-labelled using 32P-ATP and T4
polynucleotide kinase and mixed with the corresponding unla-A/LNA (ON2), MP-DNA/DNA (ON3) and MP-DNA/LNA (ON4) oligomers (9-mer). The
K. Nagahama et al. / Bioorg. Med. Chem. Lett. 19 (2009) 2707–2709 2709belled ON prior to digest reactions. These were performed at 25 C
in 8 lL of the following buffer: 0.1 M Tris–HCl pH 8.0, 0.1 M NaCl,
14 mM MgCl2. In each reaction, 5 pmol of the ON was digested
with 0.002 U of SVPDE (Crotalus adamanteus). The reactions were
stopped by addition of 1 lL of a solution containing formamide
and EDTA to a 1 lL sample of the reaction mixture, and the reac-
tion products were analyzed by denaturing PAGE (20%). Although
improvement in the stability towards 30-exonuclease degradation
by introduction of LNA into a DNA strand has been reported,16,39,40
we here observed complete and rapid degradation of all-DNA ON1
and LNA-modified ON2 (Fig. 2). MP-DNA/DNA ON3 showed signif-
icantly improved resistance but complete degradation was seen
after 60 min of incubation. In contrast, MP-DNA/LNA ON4 was
remarkably stable with more than 50% full-length compound
remaining after 60 min of incubation. The resistance against 30-
exonucleolytic degradation induced by a MP-DNA monomer is fur-
thermore visualized by the emergence of an intermediate length
band during degradation of ON3 and ON4. We assign these bands
as 6-mer ONs resulting from cleavage of three nucleotides from
ON3 and ON4. These results demonstrate that MP-DNA/DNA/LNA
chimeric ONs having MP-DNA and LNA monomers dispersed with
standard DNA monomers are significantly more stable against
nucleolytic degradation than all-DNA or DNA/LNA chimeric ONs.
The high resistance of MP-DNA/LNA chimeric ONs is resulting from
combined effects of the MP-linkages and the LNA moieties.
In summary, we herein have introduced chimeric methylphos-
phonate-DNA/LNA oligomers as a new class of potential AONs.
These constructs display high-affinity RNA targeting, and the com-
bination of methylphosphonate-DNA with DNA and LNA mono-
mers efficiently inhibits 30-exonucleolytic degradation. Chimeric
methylphosphonate-DNA/LNA oligonucleotides therefore consti-
tute an alternative to phosphorothioate-DNA/LNA oligonucleotides
for antisense applications, and the neutral methylphosphonate
linkages can be foreseen to alter the biodistribution relative to cur-
rently applied antisense molecules. All nucleotide building blocks
necessary to synthesize these novel constructs are commercially
available and no significant synthetic hurdles prevent their evalu-
ation as antisense agents in cell culture and in vivo. We thus be-
lieve that methylphosphonate-DNA/LNA oligonucleotides have
potential for practical antisense applications aiming at mRNA and
miRNA targeting.
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